FR940419-2-00077 FR940419-2-00039 [Docket No. 94M&hyph;0065] Leocor, Inc.; Premarket Approval of Corflo TM Models 5S, 7.5S, and 7.5PT PTCA Catheter and Hemoperfusion Pump AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the supplemental application by Leocor, Inc., Houston, TX, for premarket approval, under section 515 of the Federal Food, Drug, and Cosmetic Act (the act), of the Corflo TM Models 5S, 7.5S, and 7.5PT PTCA Catheter and Hemoperfusion Pump. After reviewing the recommendation of the Circulatory System Devices Panel, FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of February 15, 1994, of the approval of the supplemental application. DATES: Petitions for administrative review by May 19, 1994. ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857. FOR FURTHER INFORMATION CONTACT: Tara A. Ryan, Center for Devices and Radiological Health (HFZ&hyph;450), Food and Drug Administration, 1390 Piccard Dr., Rockville, MD 20850, 301&hyph;594&hyph;1197. SUPPLEMENTARY INFORMATION: On December 3, 1990, Leocor, Inc., Houston, TX, 77058, submitted to CDRH a supplemental application for premarket approval of the Corflo TM Models 5S, 7.5S, and 7.5PT PTCA Catheter and Hemoperfusion Pump. The device is indicated as follows: Percutaneous transluminal coronary angioplasty (PTCA) can be indicated by the physician in patients with significant coronary artery disease who are acceptable candidates for coronary artery bypass graft surgery and who meet one of the following selection criteria: Single or multiple vessel atherosclerotic coronary artery disease that is concentric and accessible to a dilation catheter. Coronary artery disease of the native coronary arteries and/or coronary artery bypass grafts of some patients who have previously undergone coronary artery bypass graft surgery and who have recurrence of symptoms and (a) progression of disease or (b) stenosis and closure of the grafts. Hemoperfusion can be indicated by the physician in patients who cannot tolerate the inflation times necessary to achieve the desired stenosis reduction. Intolerance to inflation is demonstrated by anginal pain and/or ST segment elevation, and/or hemodynamic instability (systemic blood pressure drop) and/or arrhythmias. On June 4, 1991, the Circulatory System Devices Panel of the Medical Devices Advisory Committee, an FDA advisory committee, reviewed and recommended approval of the supplemental application. On February 15, 1994, CDRH approved the supplemental application by a letter to the applicant from the Acting Director of the Office of Device Evaluation, CDRH. A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document. Opportunity for Administrative Review Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, under section 515(g) of the act (21 U.S.C. 360e(g)), for administrative review of CDRH's decision to approve this application. A petitioner may request either a formal hearing under part 12 (21 CFR part 12) of FDA's administrative practices and procedures regulations or a review of the application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under ยง10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a notice of its decision in the Federal Register . If FDA grants the petition, the notice will state the issue to be reviewed, the form of review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details. Petitioners may, at any time on or before May 19, 1994, file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Devices and Radiological Health (21 CFR 5.53). Dated: April 5, 1994. Joseph A. Levitt, Deputy Director for Regulations Policy, Center for Devices and Radiological Health. [FR Doc. 94&hyph;9355 Filed 4&hyph;18&hyph;94; 8:45 am] BILLING CODE 4160&hyph;01&hyph;F
